PDB73 Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective  by Charokopou, M. et al.
A344  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
Objectives: Two SGLT-2 inhibitors, CANA and DAPA, are recommended in the UK 
for combination therapy in T2DM. Through an insulin-independent mechanism of 
action, SGLT-2 inhibitors improve glucose levels, blood pressure, and weight with a 
low inherent risk of hypoglycaemia. The cost-effectiveness of using CANA or DAPA 
in combination with MET was evaluated in patients inadequately controlled with 
MET monotherapy, from the perspective of the UK NHS. MethOds: The ECHO-
T2DM model was used to estimate 40-year outcomes and costs associated with 
using CANA (100mg or 300mg) versus DAPA 10mg in dual therapy. HbA1c efficacy 
estimates were obtained from a Network Meta-Analysis (NMA). Analyses of pooled 
data from trials investigating CANA dual therapy (with MET) were used for param-
eters unavailable in the NMA (i. e., SBP, LDL, HDL and AEs). A broad set of sensitiv-
ity analyses were performed. Results: Both doses of CANA were associated with 
more QALYs (0.01,0. 03 for 100mg and 300mg, respectively) and higher costs (£101, 
£594, respectively). The associated incremental cost-effectiveness ratios (ICERs) were 
£7,423 and £17,734, respectively; both below the willingness-to-pay for QALY thresh-
old in the UK. The key driver of the result for CANA 300mg was the greater HbA1c 
efficacy versus DAPA 10mg, and for CANA 100mg, a lower need for insulin rescue 
since CANA (but not DAPA) can be used in persons with moderate renal impair-
ment. The ICERs were robust under all scenarios tested. Only use of UK-specific and 
not clinical trial patient characteristics substantively impacted the results; none 
reversed the interpretation of CANA as cost-effective versus DAPA. cOnclusiOns: 
SGLT-2 inhibitors reduce HbA1C, body weight, and blood pressure, and thus the risk 
of micro- and macrovascular complications. Economic simulations suggest that 
both doses of CANA are cost-effective versus DAPA in dual therapy treatment of 
T2DM (with MET) in the UK.
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Objectives: To project the long-term costs and outcomes of sensor-augmented 
pump (SAP) with low glucose suspend (LGS) versus insulin pump (CSII) alone for the 
treatment of hypo-prone Type 1 diabetes in Hungary. MethOds: The CORE Diabetes 
Model is a peer-reviewed, validated model, which employs standard Markov/Monte 
Carlo simulation techniques to describe the long-term incidence and progression 
of diabetes-related complications. It was used to simulate disease progression in a 
cohort of patients with baseline characteristics (mean age 18.6 years, duration of 
diabetes 12 years, mean HbA1c 7.5%) and clinical outcomes (severe hypoglycaemic 
event rates; Quality of Life; HbA1c) taken from a recent randomised controlled 
trial (Ly et al, 2013). Local treatment and complication cost data was used. The 
main scenario considered in this cost-effectiveness analysis was the comparison 
of sensor-augmented insulin pump (SAP) with low glucose suspend (LGS) versus 
pump alone (CSII). The target population was hypo-prone type I diabetes patients 
with the analysis based on a deterministic microsimulation of 1,000 patients, using 
a 1 to 5 year time horizon. Direct costs were calculated from a third-party payer 
perspective. Discount rates of 3.7% per annum were applied to both costs and 
clinical outcomes. Results: The Incremental-Cost-Effectiveness-Ratio (ICER) for 
SAP+LGS vs CSII was HUF 6,196,086 (€ 20,298) per Quality-Adjusted-Life-Year gained 
over a 1 year time horizon. Results were similar using a 5 year time horizon (HUF 
6,125,823 [€ 20,068] per QALY gained). Extensive sensitivity analyses showed the 
robustness of the results. cOnclusiOns: Using a payer’s perspective, our analysis 
showed that SAP (w LGS) is cost-effective over a short term (1-5 year) time horizon 
in hypo prone patients with Type 1 Diabetes in Hungary (using a WTP threshold of 
3x Hungary GDP).
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Objectives: New classes of anti-diabetes drugs may delay the onset of Insulin 
treatment. This study investigates the cost-effectiveness of a treatment path-
way starting with dapagliflozin (Forxiga®), followed by exenatide once weekly 
(Bydureon®) - both as add-on to metformin - and insulin treatment, compared 
with a treatment pathway recommended in clinical guidelines that commences 
with SU add-on to metformin, followed by the addition of insulin regimens in 
patients inadequately controlled with metformin alone. MethOds: The validated 
CARDIFF model was used for the analyses. Clinical inputs for dapagliflozin ver-
sus SU, both as add-on to metformin, and exenatide once weekly were derived 
from relevant head-to-head clinical trials and long-term follow up studies. Based 
on these and the United Kingdom Prospective Diabetes Study (UKPDS) equations, 
the model predicts disease progression and number of micro- and macro-vascular 
complications, along with diabetes-specific and all-cause mortality. The perspec-
tive of the National Health Service in UK was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters 
to calculate total Quality-Adjusted-Life-Years (QALYs) and costs. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted. Results: Long-term 
evidence showed that the durability of the treatment effects of dapagliflozin and 
exenatide can delay the onset of insulin treatment by 5-6 years. Compared to the 
traditional clinical practice, treatment with dapagliflozin+metformin followed by 
exenatide+metformin, was associated with an incremental benefit of 0.343 QALYs 
(95%CI: 0.239; 0.450) at an additional cost of £2,827 (95%CI: £2,352; £3,267), result-
ing in an incremental cost-effectiveness ratio of £8,233 per QALY gained. The PSA 
and results in higher QALYs in comparison with sitagliptin 100 mg in dual therapy as 
add-on to metformin and in triple therapy as add-on to MET plus SU. In dual therapy 
as add-on to MET, canagliflozin (100 mg and 300 mg weighted average 65: 35) has 
an average cost saving of 24 € and an average QALY gain of 0.036. In triple therapy 
as add-on to MET+SU, canagliflozin (100 mg and 300 mg weighted average 65: 35) 
has an average cost saving of 171 € and an average QALY gain of 0.033. Probabilistic 
analysis suggests a likelihood of 59% of canagliflozin being cost-effective compared to 
sitagliptin in dual therapy and 59% in triple therapy at a willingness-to-pay of 30,000 
€ per gained QALY. Sensitivity analyses showed that canagliflozin is cost-effective 
also from a payer perspective and even when the time horizon, which is 30 years in 
the base case, is reduced to 10 years. cOnclusiOns: Canagliflozin 100 mg and 300 
mg will be a cost-effective alternative to sitagliptin in both dual and triple therapies, 
as add-on to MET or as add-on to MET+SU, respectively.
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Objectives: Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor 
developed for the treatment of adult patients with type 2 diabetes mellitus (T2DM). 
To evaluate the cost-effectiveness of canagliflozin in dual therapy as add-on to 
metformin (MET) compared to sitagliptin, and in triple therapy (add on to MET 
and sulphonylurea (SU)) compared to sitagliptin, liraglutide and a mixed strategy 
with both drugs. MethOds: The IMS CORE Diabetes Model was used to evaluate 
the cost-effectiveness of canagliflozin versus the aforementioned comparators 
using French-specific data, where available. Results: In dual therapy, as add-
on to metformin versus sitagliptin, canagliflozin (100 mg and 300 mg weighted 
average 50: 50) resulted in an incremental cost of 392 € and an average QALY gain 
of 0.013, which leads to an ICER of 30,154 € . In triple therapy canagliflozin (100 
mg and 300 mg weighted average 50: 50) dominates sitagliptin with average cost 
savings of 286 € and an average QALY gain of 0.050. Canagliflozin was estimated 
to be cost-saving (1,280 € ) compared to liraglutide (distribution liraglutide 1.2 
mg / 1.8 mg= 0.71/0.29 based on French market research data) with incremen-
tal QALYs of -0.015. Canagliflozin (100 mg and 300 mg weighted average 50: 50) 
dominates a mixed strategy with liraglutide (12.5%) and sitagliptin (87.5%) average 
cost saving of 410 € and average QALY gain of 0.041. Sensitivity analyses showed 
that HbA1cand SBP treatment effects were key drivers of the cost effectiveness 
results. cOnclusiOns: Canagliflozin 100 mg and 300 mg will be a cost-effective 
alternative to sitagliptin in dual therapy as add-on to metformin. In triple therapy 
as add-on to metformin and SU, canagliflozin dominates in comparison with a 
mix of patients treated with sitagliptin or liraglutide. Canagliflozin 100 mg or 
300 mg is expected to be considered good value for money for the treatment of 
T2DM in France.
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Objectives: In patients with type 2 diabetes (T2D) receiving basal insulin therapy, 
the addition of bolus insulin is a common therapeutic strategy once glycated hemo-
globin (HbA1c) becomes uncontrolled. However, this strategy is associated with 
weight gain and increased risk of hypoglycemia. The objective was to assess the 
cost-effectiveness of exenatide twice daily (BID) (‘ExBID’) versus insulin lispro three 
times daily (TID) (‘LisTID’) as add-on therapy to titrated insulin glargine in patients 
with T2D, from the Swedish health care perspective. MethOds: This analysis uti-
lized the Cardiff Model, a previously published T2D disease model. Treatment effects 
were taken from the 4B Study, where ExBID and LisTID resulted in similar glycemic 
control with less hypoglycemia with ExBID. Furthermore, ExBID was associated 
with a weight loss of 2.6kg and LisTID with a weight gain of 1.9kg. An assumption 
made in this analysis is that once the HbA1c level returned to its baseline value, 
patients escalated to intensified basal-bolus therapy based on published treatment 
effects. Quality-adjusted life years (QALYs) were calculated, with health-state utili-
ties applied to weight changes, hypoglycemia, and T2D-related complications. Costs 
(Swedish kronor, SEK) included medication and T2D-related complications. The 
model was run over a 40-year time horizon. Costs and QALYs were discounted at 
3% annually. Results: Cost/patient with ExBID and LisTID was SEK 381,177 and 
SEK 364,381, respectively. ExBID was associated with a QALY gain of 0.64 per patient 
versus LisTID (11.51 and 10.86 QALYs, respectively). This result was driven by the 
difference in weight between ExBID and LisTID. The cost/QALY gained with ExBID 
versus LisTID was SEK 26,292. cOnclusiOns: With a cost/QALY gained of SEK 
26,292 (3,039 Euros, 2,582 British pounds, 4,033 US dollars), evaluated against com-
monly used cost-effectiveness threshold values, ExBID represents a cost-effective 
treatment alternative to LisTID as add-on therapy to titrated insulin glargine in 
patients with T2D in Sweden.
PDB71
tHe cost-effectiVeness of canagliflozin (cana) Versus DaPagliflozin 
(DaPa) in Patients WitH tyPe 2 DiaBetes mellitus (t2Dm) WitH 
inaDequate control on metformin (met) monotHeraPy in tHe uniteD 
kingDom
Schroeder M.1, Johansen P.2, Thompson G.1, Willis M.3, Neslusan C.4
1Janssen-Cilag UK, High Wycombe, UK, 2The Swedish Institute for Health Economics (IHE), Lund, 
Sweden, 3The Swedish Institute for Health Economics, Lund, Sweden, 4Janssen Global Services, 
LLC, Raritan, NJ, USA
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A345
were sourced from the literature. Both costs and outcomes were discounted at 
5%. Results: Incremental costs, QALYs and ICERs for canagliflozin vs. sitagliptin 
were € 1,360, 0.059 QALYs and € 23,118 per QALY, respectively, in dual therapy; € 108, 
0.093 QALYs and € 1,172 per QALY, respectively, in triple therapy; and € 550, 0.068 
QALYs and € 8,047 per QALY, respectively, in add-on to insulin. In all three scenarios, 
canagliflozin was cost-effective using the acceptable willingness-to-pay threshold in 
Ireland. Sensitivity analyses suggest that these results are robust. cOnclusiOns: 
These simulations suggest that the use of canagliflozin in patients in need of addi-
tional glycaemic control in dual, triple and add-on to insulin lines of therapy is a 
more efficient use of health care funds than the use of sitagliptin in the Irish setting.
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Objectives: Canagliflozin is a novel oral agent for the treatment of T2DM that 
inhibits sodium-glucose co-transporter 2 (SGLT2), a mechanism that is comple-
mentary to other anti-hyperglycaemic drug classes, including insulin. SGLT2 
inhibition leads to inhibition of glucose reabsorption and urinary glucose excre-
tion, thereby reducing blood glucose, weight, and blood pressure. An economic 
(cost-effectiveness) evaluation of new technologies versus routine care is required 
prior to uptake in Ireland to ensure good value-for-money. This study evaluates 
the cost-effectiveness of canagliflozin compared to liraglutide – a currently reim-
bursed and routinely used glucagon-like peptide 1 (GLP-1) agonist – as dual therapy 
in combination with metformin from the payer perspective in the Irish health 
care setting. MethOds: The Economic and Health Outcomes Model of T2DM 
(ECHO-T2DM) [using updated UKPDS 82 mortality and risk equations] was used 
to simulate 40-year costs and outcomes associated with canagliflozin (100mg 
titrated to 300mg in patients requiring tighter glycaemic control) compared to 
liraglutide 1.2mg. Patient characteristics were sourced from canagliflozin RCTs 
in patients uncontrolled on metformin monotherapy and treatment effects were 
obtained from a network meta-analysis. The costs of treatments and outcomes 
were localised and inflated to 2013 values where possible. Utilities were sourced 
from the literature. Costs and outcomes were discounted at 5% annually. Results: 
In the base case, canagliflozin was associated with incremental cost savings of 
€ 3,382 compared to liraglutide 1.2mg. It was also associated with a 0.022 more life 
years and 0.020 more quality adjusted life years (QALYs), suggesting that cana-
gliflozin dominates liraglutide. Results were driven by lower acquisition costs for 
canagliflozin. Sensitivity analyses indicated that the dominance observed was 
robust. cOnclusiOns: In these simulations, canagliflozin dominated liraglutide 
1.2mg in dual therapy (add-on to metformin) in the Irish setting. These results 
suggest that canagliflozin represents good ‘value for money’ in treating these 
patients, compared to a routinely used GLP-1 agonist.
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Objectives: Canagliflozin is a novel drug for treatment of diabetes belonging to the 
drug class known as sodium glucose co-transporter 2 (SGLT2) inhibitors. To evalu-
ate the cost-effectiveness of canagliflozin in dual therapy (add-on to metformin) 
compared to sitagliptin and sulfonylurea (SU), in triple therapy (add on to metformin 
and SU) compared to sitagliptin and as add-on to insulin versus placebo. MethOds: 
The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of cana-
gliflozin (using a weighted average of 80/20 for the 100 mg and 300 mg dosage, 
respectively) versus the aforementioned comparators using Norwegian-specific 
data, where available. Results: In dual therapy, as add-on to metformin versus 
sitagliptin, canagliflozin appears to dominate sitagliptin with average cost sav-
ings of 606 NOK and an average QALY gain of 0.030 and as add on to metformin 
canagliflozin is cost-effective versus SU, with an incremental cost-effectiveness 
ratio (ICER) of 79,309 NOK and an incremental cost of 5,757.80 NOK and an aver-
age QALY gain of 0.0726. As add on to insulin canagliflozin appears to dominate 
placebo with an incremental cost saving of 13,506 NOK and an incremental QALY 
of 0.080. In triple therapy as add on to metformin and SU canagliflozin appears to 
dominate sitagliptin with average cost savings of 556 NOK and an average QALY 
gain of 0.021. cOnclusiOns: Canagliflozin is associated with cost savings and 
QALY gain compared to sitagliptin in dual therapy as add-on to metformin, and in 
triple therapy as add on to metformin and SU. Canagliflozin will be a cost-effective 
alternative to SU in dual therapy as add on to metformin. Adding canagliflozin to 
insulin will be cost-effective compared with placebo i. e. it is cost-effective to add 
canagliflozin treatment rather than not.
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Objectives: To project the long-term costs and outcomes of sensor-augmented 
pump (SAP) with low glucose suspend (LGS) versus insulin pump alone (CSII) for 
the treatment of hypo-prone Type 1 diabetes in Slovakia. MethOds: The CORE 
Diabetes Model is a peer-reviewed, validated model, which employs standard 
showed that at a willingness-to-pay threshold of £20,000 per QALY, the proposed 
treatment pathway had a 100% probability to be cost-effective. cOnclusiOns: 
The proposed alternative treatment sequence was shown to be a cost-effective 
treatment option in patients inadequately controlled with metformin alone within 
established UK cost-effectiveness thresholds.
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Objectives: To evaluate the long-term cost-effectiveness of liraglutide versus sit-
agliptin or exenatide, added to oral antidiabetic drug mono- or combination ther-
apy respectively, in patients with Type 2 diabetes in Greece. MethOds: The CORE 
Diabetes Model, a validated computer simulation model developed to determine 
the long-term health and economic outcomes of interventions in Type 2 diabe-
tes, was adapted to the Greek health care setting. Patient and intervention effects 
data were gathered from a clinical trial comparing liraglutide 1.2mg once daily 
vs. sitagliptin 100mg once daily, both combined with metformin, and a clinical 
trial comparing liraglutide 1.8mg once daily vs. exenatide 10μ g twice daily, both as 
add-on to metformin, glimepiride or both. Direct costs were reported in 2013 Euros 
and calculated based on published and local sources. All future outcomes were 
discounted at 3.5% per annum, and the analysis was conducted from the perspec-
tive of a third-party payer in Greece. Results: Over a patient’s lifetime, treatment 
with liraglutide 1.2mg vs. sitagliptin drove a mean increase in discounted life expec-
tancy of 0.13 (SD 0.23) years and in discounted quality-adjusted life expectancy 
of 0.19 (0.16) quality-adjusted life years (QALYs), whereas therapy with liraglutide 
1.8mg vs. exenatide yielded increases of 0.14 (0.23) years and 0.19 (0.16) QALYs 
respectively. As regards lifetime direct costs, liraglutide 1.2mg resulted in greater 
costs of € 2797 (€ 1468) versus sitagliptin, and so did liraglutide 1.8mg compared 
with exenatide (€ 1302 [€ 1492]). Liraglutide 1.2 and 1.8mg doses were associated 
with incremental cost effectiveness ratios of € 15101 and € 6818 per QALY gained, 
respectively. cOnclusiOns: Liraglutide is likely to be a cost-effective option for 
the treatment of Type 2 diabetes in a Greek setting.
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Objectives: Canagliflozin is a novel drug for treatment of diabetes belonging to 
the drug class known as sodium glucose co-transporter–2 (SGLT-2) inhibitors. To 
evaluate the cost-effectiveness of canagliflozin 100 mg in the Slovakian setting 
from a payer perspective when compared to sitagliptin in dual therapy (add-on to 
metformin), sitagliptin in triple therapy (add-on to metformin plus sulfonylurea) and 
dapagliflozin in combination with insulin (with or without metformin). MethOds: 
The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of cana-
gliflozin versus comparators using Slovakia specific data, where available. Results: 
The cost-effectiveness analyses indicated that canagliflozin 100 mg in dual therapy 
when compared with sitagliptin, was found to be cost-effective with an incremental 
cost-effectiveness ratio (ICER) of 14,930 € per QALY gained. In triple therapy when 
compared to sitagliptin, canagliflozin 100 mg was found to be cost-effective with 
an ICER of 5,251 € per QALY gained and in combination with insulin, canagliflozin 
100 mg was a dominant alternative compared to dapagliflozin with a cost saving of 
118 € per patient and higher QALYs. One-way sensitivity analyses revealed that in 
the majority of scenarios considered canagliflozin remained cost-effective in the 
dual therapy, triple therapy and add-on to insulin comparisons. cOnclusiOns: 
Based on calculations performed using the CORE Diabetes model, canagliflozin 100 
mg appear to represent a cost-effective option for the treatment of type 2 diabetes 
in Slovakia. Canagliflozin 100 mg was found to offer greater health benefits than 
currently available alternatives and to be a cost-effective treatment option when 
used in dual and triple therapy instead of sitagliptin or as an add-on to insulin 
instead of dapagliflozin.
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Objectives: Canagliflozin is a new oral agent for the treatment of T2DM that inhib-
its sodium-glucose co-transporter 2 (SGLT2), thereby leading to inhibition of glucose 
reabsorption and urinary glucose excretion which results in reductions in blood 
glucose, weight, and blood pressure. The purpose of this analysis was to evaluate 
the cost-effectiveness of canagliflozin vs. sitagliptin – a recommended and widely 
used dipeptidyl peptidase-4 inhibitor (DPP4) – in dual (with metformin), triple (with 
metformin + sulphonylurea) and add-on to basal insulin (with or without other 
anti-hyperglycaemic agents) therapy lines in Ireland. MethOds: The Economic and 
Health Outcomes Model of T2DM (ECHO-T2DM) [using updated UKPDS 82 mortality 
and risk equations] was used to simulate lifetime outcomes and costs of patients 
on either canagliflozin (100mg, titrated to 300mg as needed to maintain glycaemic 
control) or sitagliptin 100mg. Patient characteristics and treatment effects were 
sourced from head to head randomized clinical trials for dual and triple therapy. 
For the add-on to insulin therapy simulations, treatment effects were sourced from 
a network meta-analysis. Costs were localised and inflated to 2013 euros. Utilities 
